RESUMEN
Treatment of the bleeding syndrome in Glanzmann thrombasthenia (GT) is often complicated by naturally occurring isoantibodies directed against the αIIbß3 integrin that cause the removal of or render ineffective transfused donor platelets. Such antibodies are produced after transfusion or pregnancy when the patient's immune system comes into contact with normal platelets. Despite many reports of anti-αIIbß3 antibodies in GT patients, there is no consensus pertaining to their frequency, their long-term evolution in the circulation, or their formation in relation to either (i) the extent of the αIIbß3 deficiency in the patient's platelets or (ii) the nature of the genetic defect (ITGA2B or ITGB3 genes). Antibody screening was performed on a large series of 24 GT patients in South-West France dividing the patients into two cohorts: (i) 16 patients with the French gypsy mutation (c.1544 + 1G>A) within ITGA2B that gives platelets totally lacking αIIbß3 and (ii) 8 patients carrying other defects of ITGA2B or ITGB3 with different expression levels of αIIbß3. Our results confirm that patients with premature termination mutations resulting in platelets lacking αIIbß3 are the most susceptible to form isoantibodies, a finding that may be useful in deciding the choice of therapy between platelet transfusion and the use of recombinant factor VIIa (FVIIa).
Asunto(s)
Plaquetas/inmunología , Integrina alfa2/inmunología , Integrina beta3/inmunología , Isoanticuerpos/inmunología , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/inmunología , Trombastenia/inmunología , Adolescente , Adulto , Anciano , Niño , Preescolar , Estudios de Cohortes , Femenino , Francia , Humanos , Masculino , Persona de Mediana Edad , Mutación , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/genética , Trombastenia/genética , Adulto JovenRESUMEN
Stopping or preventing local bleeding in patients with inherited bleeding disorders linked to abnormal platelet function is traditionally treated by transfusion of blood cell products or recombinant factor VIIa. We now report the use in such patients of autologous platelet-rich clots as an aid to preventing bleeding and to facilitating tissue regeneration at superficial sites. Two patients with von Willebrand's disease (VWD) type 2B and one patient with type I Glanzmann thrombasthenia were treated after tooth extraction and dental surgery. A fourth patient with platelet-type VWD underwent a skin biopsy. Whereas all four patients had a lifelong history of bleeding complications, the application of an autologous platelet-rich clot immediately after surgery combined with tranexamic acid intake to slow fibrinolysis prevented blood loss and resulted in rapid and normal healing. This new procedure is simple, safe and inexpensive; it provides extra security for patients with a bleeding risk undergoing dentistry or superficial surgery.
Asunto(s)
Plasma Rico en Plaquetas , Hemorragia Posoperatoria/prevención & control , Trombastenia/terapia , Enfermedad de von Willebrand Tipo 1/terapia , Enfermedad de von Willebrand Tipo 2/terapia , Femenino , Humanos , Masculino , Persona de Mediana Edad , Trombastenia/cirugía , Trasplante Autólogo , Enfermedad de von Willebrand Tipo 1/cirugía , Enfermedad de von Willebrand Tipo 2/cirugíaRESUMEN
Much discussion has concerned the central role of ADP in platelet aggregation. We now describe a patient (M.L.) with an inherited bleeding disorder whose specific feature is that ADP induces a limited and rapidly reversible platelet aggregation even at high doses. Platelet shape change and other hemostatic parameters were unmodified. A receptor defect was indicated, for, while epinephrine normally lowered cAMP levels of PGE1-treated (M.L.) platelets, ADP was without effect. The binding of [3H]2-methylthio-ADP decreased from 836 +/- 126 molecules/platelet for normals to 30 +/- 17 molecules/platelet for the patient. Flow cytometry confirmed that ADP induced a much lower fibrinogen binding to (M.L.) platelets. Nonetheless, the binding in whole blood of activation-dependent monoclonal antibodies showed that some activation of GP IIb-IIIa complexes by ADP was occurring. Platelets of a patient with type I Glanzmann's thrombasthenia bound [3H]2-methylthio-ADP and responded normally to ADP in the presence of PGE1. Electron microscopy showed that ADP-induced aggregates of (M. L.) platelets were composed of loosely bound shape-changed platelets with few contact points. Thus this receptor defect has a direct influence on the capacity of platelets to bind to each other in response to ADP.
Asunto(s)
Adenosina Difosfato/metabolismo , Trastornos de la Coagulación Sanguínea/metabolismo , Plaquetas/metabolismo , Fibrinógeno/metabolismo , Receptores Purinérgicos P2/metabolismo , Adenosina Difosfato/análogos & derivados , Adenosina Difosfato/farmacología , Alprostadil/farmacología , Trastornos de la Coagulación Sanguínea/genética , Plaquetas/efectos de los fármacos , Plaquetas/ultraestructura , AMP Cíclico/metabolismo , Gránulos Citoplasmáticos , Epinefrina/farmacología , Citometría de Flujo , Humanos , Masculino , Persona de Mediana Edad , Agregación Plaquetaria , Glicoproteínas de Membrana Plaquetaria/metabolismo , Tionucleótidos/metabolismo , Población BlancaRESUMEN
Essentials There are many hereditary platelet disorders (HPD) but diagnosing these is challenging. We provide a method to diagnose several HPDs using standard blood smears requiring < 100 µL blood. By this approach, the underlying cause of HPD was characterized in ~25-30% of referred individuals. The method facilitates diagnosis of HPD for patients of all ages around the world. SUMMARY: Background Many hereditary thrombocytopenias and/or platelet function disorders have been identified, but diagnosis of these conditions remains challenging. Diagnostic laboratory techniques are available only in a few specialized centers and, using fresh blood, often require the patient to travel long distances. For the same reasons, patients living in developing countries usually have limited access to diagnosis. Further, the required amount of blood is often prohibitive for pediatric patients. Objectives By a collaborative international approach of four centers, we aimed to overcome these limitations by developing a method using blood smears prepared from less than 100 µL blood, for a systematic diagnostic approach to characterize the platelet phenotype. Methods We applied immunofluorescence labelling (performed centrally) to standard air-dried peripheral blood smears (prepared locally, shipped by regular mail), using antibodies specific for proteins known to be affected in specific hereditary platelet disorders. Results By immunofluorescence labelling of blood smears we characterized the underlying cause in 877/3217 (27%) patients with suspected hereditary platelet disorders (HPD). Currently about 50 genetic causes for HPD are identified. Among those, the blood smear method was especially helpful to identify MYH9 disorders/MYH9-related disease, biallelic Bernard-Soulier syndrome, Glanzmann thrombasthenia and gray platelet syndrome. Diagnosis could be established for GATA1 macrothrombocytopenia, GFI1B macrothrombocytopenia, ß1-tubulin macrothrombocytopenia, filamin A-related thrombocytopenia and Wiskott-Aldrich syndrome. Conclusion Combining basic and widely available preanalytical methods with the immunomorphological techniques presented here, allows detailed characterization of the platelet phenotype. This supports genetic testing and facilitates diagnosis of hereditary platelet disorders for patients of all ages around the world.
Asunto(s)
Trastornos de las Plaquetas Sanguíneas/sangre , Trastornos de las Plaquetas Sanguíneas/diagnóstico , Plaquetas/metabolismo , Pruebas Hematológicas/instrumentación , Pruebas Hematológicas/métodos , Alelos , Síndrome de Bernard-Soulier/genética , Femenino , Humanos , Inmunofenotipificación , Cooperación Internacional , Masculino , Microscopía Fluorescente , Proteínas Motoras Moleculares/genética , Cadenas Pesadas de Miosina/genética , Fenotipo , Sensibilidad y Especificidad , Trombastenia/genéticaRESUMEN
The gene variants responsible for the primary genotype of many platelet disorders have now been identified. Next-generation sequencing technology (NGST), mainly exome sequencing, has highlighted genes responsible for defects in platelet secretion (NBEAL2, gray platelet syndrome), procoagulant activity (STIM1, Stormorken syndrome), and activation pathways (RASGRP2, CalDAG-GEFI deficiency and integrin dysfunction; PRKACG, cyclic adenosine monophosphate-dependent protein kinase deficiency). Often disorders of platelet function are associated with a modified platelet production with changes in platelet number and size and can accompany malfunction of other organs or tissues. Most families have private mutations, and gene variants may prevent protein synthesis, abrogate function, or result in aberrant activated proteins. Nevertheless, bleeding severity is difficult to predict by genotype alone suggesting other factors. A major new challenge of NGST is to identify these factors and help improve patient care. This review concentrates on recent developments and is illustrated from personal observations.
Asunto(s)
Trastornos de las Plaquetas Sanguíneas/genética , Plaquetas/metabolismo , Variación Genética , Hemorragia/genética , Hemostasis/genética , Mutación , Animales , Trastornos de las Plaquetas Sanguíneas/sangre , Trastornos de las Plaquetas Sanguíneas/diagnóstico , Análisis Mutacional de ADN/métodos , Marcadores Genéticos , Predisposición Genética a la Enfermedad , Herencia , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Fenotipo , Factores de Riesgo , Transducción de SeñalRESUMEN
We have tested the DNA of a large series of Glanzmann thrombasthenia patients for polymorphisms in platelet membrane glycoproteins. To our surprise, we noted a high prevalence of the HPA-1b allele of beta3, the minority allele in a normal population. This proved to be due to the presence of nine patients homozygous for the so-called French gypsy mutation (IVS15[ + 1]G-->A) in alphaIIb. Seven of these patients were homozygous for the HPA-1b alloantigen and the other two heterozygous HPA-1a/1b. As the alphaIIb and beta3 genes are both on chromosome 17, it is highly probable that the French gypsy mutation first arose on a chromosome encoding HPA-1b. For other adhesion receptors, no major differences were seen in the distribution of the A1, A2 and A3 alleles in the alpha2 gene, or in the Kozak or HPA-2 polymorphisms of GPIbalpha, suggesting that none of these alleles result in increased survival in Glanzmann thrombasthenia.
Asunto(s)
Ligamiento Genético , Glicoproteínas de Membrana Plaquetaria/genética , Polimorfismo Genético , Trombastenia/genética , Sustitución de Aminoácidos , Antígenos de Plaqueta Humana/genética , Pruebas Genéticas , Genotipo , Humanos , Integrina beta3/genética , Desequilibrio de Ligamiento , Mutación Missense , Glicoproteína IIb de Membrana Plaquetaria/genética , Trombastenia/sangreRESUMEN
von Willebrand factor (VWF) is a complex plasma glycoprotein that modulates platelet adhesion at the site of a vascular injury, and it also serves as a carrier protein for factor (F)VIII. As megakaryocytes are the only hematopoietic lineage to naturally synthesize and store VWF within alpha-granules, this study was performed to determine if expression of a FVIII transgene in megakaryocytes could lead to trafficking and storage of FVIII with VWF in platelet alpha-granules. Isolex selected CD34+ cells from human G-CSF mobilized peripheral blood cells (PBC) and murine bone marrow were transduced with a retrovirus encoding the B-domain deleted form of human FVIII (BDD-FVIII). Cells were then induced with cytokines to form a population of multiple lineages including megakaryocytes. Chromogenic analysis of culture supernatant from FVIII-transduced human cells demonstrated synthesis of functional FVIII. Treatment of cells with agonists of platelet activation (ADP, epinephrine, and thrombin receptor-activating peptide) resulted in the release of VWF antigen and active FVIII into the supernatant from transduced cells. Immunofluorescence analysis of cultured human and murine megakaryocytes revealed a punctate pattern of staining for FVIII that was consistent with staining for VWF. Electron microscopy of transduced megakaryocytes using immunogold-conjugated antibodies colocalized FVIII and VWF within the alpha-granules. FVIII retained its association with VWF in human platelets isolated from the peripheral blood of NOD/SCID mice at 2-6 weeks post-transplant of transduced human PBC. These results suggest feasibility for the development of a locally inducible secretory pool of FVIII in platelets of patients with hemophilia A.
Asunto(s)
Factor VIII/biosíntesis , Factor VIII/metabolismo , Megacariocitos/metabolismo , Transducción Genética , Animales , Técnicas de Cultivo de Célula/métodos , Linaje de la Célula/efectos de los fármacos , Gránulos Citoplasmáticos/química , Factor VIII/genética , Terapia Genética/métodos , Trasplante de Células Madre Hematopoyéticas , Células Madre Hematopoyéticas/citología , Células Madre Hematopoyéticas/metabolismo , Hemofilia A/tratamiento farmacológico , Humanos , Megacariocitos/citología , Ratones , Ratones SCID , Transporte de Proteínas/efectos de los fármacos , Factor de von Willebrand/metabolismoRESUMEN
Lesions in the genes for GPIb alpha, GPIb beta or GPIX result in a bleeding diathesis, the Bernard-Soulier syndrome (BSS), which associates a platelet adhesion defect with thrombocytopenia, giant platelets and abnormal megakaryocytes (MK). The role of GPV, also absent in BSS, was recently addressed by gene targeting in mice. While a negative modulator function for GPV on thrombin-induced platelet responses was found in one model, the absence of GP V had no effect on GPIb-IX expression or platelet adhesion. Our study extends previous results and reports that electron microscopy of bone marrow from the GPV knockout mice revealed a normal MK ultrastructure and development of the demarcation membrane system (DMS). There was a usual presence of MK fragments in the bone marrow vascular sinus. Immunogold labelling of MK from the knockout mice showed a normal distribution of GPIb-IX in the DMS and on the cell surface. The distribution of fibrinogen, vWF and P-selectin was unchanged with, interestingly, P-selectin also localised within the DMS in both situations. Thus GPV is not crucial to MK development and platelet production, consistent with the fact that no mutation in the GPV gene has as yet been described in BSS.
Asunto(s)
Megacariocitos/ultraestructura , Complejo GPIb-IX de Glicoproteína Plaquetaria/efectos de los fármacos , Complejo GPIb-IX de Glicoproteína Plaquetaria/farmacología , Glicoproteínas de Membrana Plaquetaria/farmacología , Animales , Síndrome de Bernard-Soulier/sangre , Factores de Coagulación Sanguínea/efectos de los fármacos , Factores de Coagulación Sanguínea/metabolismo , Trastornos de las Plaquetas Sanguíneas/genética , Trastornos de las Plaquetas Sanguíneas/metabolismo , Plaquetas/citología , Plaquetas/efectos de los fármacos , Células de la Médula Ósea/citología , Células de la Médula Ósea/efectos de los fármacos , Células de la Médula Ósea/ultraestructura , Gránulos Citoplasmáticos/química , Modelos Animales de Enfermedad , Fibrinógeno/efectos de los fármacos , Fibrinógeno/metabolismo , Inmunohistoquímica , Megacariocitos/química , Megacariocitos/efectos de los fármacos , Ratones , Ratones Noqueados , Ratones Transgénicos , Microscopía Electrónica , Selectina-P/efectos de los fármacos , Selectina-P/metabolismo , Complejo GPIb-IX de Glicoproteína Plaquetaria/genética , Complejo GPIb-IX de Glicoproteína Plaquetaria/metabolismo , Glicoproteínas de Membrana Plaquetaria/genética , Glicoproteínas de Membrana Plaquetaria/metabolismo , Subunidades de Proteína , Receptores de Superficie Celular/genética , Receptores de Superficie Celular/metabolismo , Factor de von Willebrand/efectos de los fármacos , Factor de von Willebrand/metabolismoRESUMEN
We report the defects responsible for Glanzmann thrombasthenia in two patients showing traces of abnormally migrating platelet beta3 in immunoblotting. Using PCR-SSCP and direct sequencing, we identified a novel homozygous mutation in exon 10 of the beta3 gene of patient 1 which gave a C457 to Y amino acid substitution. A C542 to R substitution in beta3 of patient 2 was previously reported by us. These cysteines are present in EGF-domains 1 and 3 respectively of beta3. We therefore constructed mutants carrying substitutions on cysteine residues in each of the first three EGF domains of beta3, C457, C495 and C542 respectively. Transient expression of these mutants in COS-7 cells, including the C542 and C547 double mutant, proved that disulfide disruption directly affects cell surface expression of the integrin. We then showed by metabolic (35S) labeling and Endo-H glycosidase treatment that these substitutions strongly affected complex maturation within the cell.
Asunto(s)
Cisteína/genética , Integrina beta3/genética , Mutación , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/biosíntesis , Trombastenia/genética , Sustitución de Aminoácidos , Análisis Mutacional de ADN , Disulfuros , Femenino , Homocigoto , Humanos , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/genética , Estructura Terciaria de Proteína , Trombastenia/etiologíaRESUMEN
ADP, a primary stimulus of platelets, binds to one or more populations of receptors on the platelet surface. These receptors are linked to discrete activation pathways. Both G proteins and tyrosine kinases have been implicated in the cellular responses to this agonist. We have studied a patient with a congenital abnormality of ADP-induced platelet aggregation in an effort to gain information on the signalling pathways used by ADP. Immunoblotting with a broadly reactive rabbit antibody recognizing the GTP-binding domain of G protein alpha-subunits, and with rabbit antibodies specific for Gialpha1-3, and Galpha12 all showed normal reactivity when tested against the patient's platelets. The phosphorylation of proteins was studied using an anti-phosphotyrosine MoAb (4G10) and platelets stimulated in a platelet aggregometer with ADP, a thromboxane A2 mimetic (IBOP), TRAP-14-mer peptide and alpha-thrombin. With normal platelets, a time-dependent phosphorylation of several bands in the 60 to 130 kDa mol. wt. range was observed with all agonists. For the patient, minimal aggregation and little or no phosphorylation of proteins of 80-85 kDa (cortactin), 100-105 kDa and 125-130 kDa were seen in response to ADP. The aggregation and phosphorylation responses were slightly modified in the presence of low doses of thrombin but were normal with high doses. Aggregation and tyrosine phosphorylation were virtually absent with IBOP, a finding reproduced when normal platelets were incubated with IBOP and the CP/CPK ADP scavenging system, thereby underlining the role of ADP in the response to IBOP. Our results show that the ADP receptor pathway deficient in the patient is linked to a selective tyrosine phosphorylation response.
Asunto(s)
Adenosina Difosfato/metabolismo , Plaquetas/fisiología , Receptores Purinérgicos P2/metabolismo , Transducción de Señal/fisiología , Tirosina/metabolismo , Animales , Fosforilación , Activación Plaquetaria , ConejosRESUMEN
In idiopathic thrombocytopenic purpura (ITP), autoantibodies reacting with antigens on the platelet membrane bring about accelerated platelet destruction. We now report PAICA ("Platelet-Associated IgG Characterization Assay"), a method for detecting autoantibodies bound to specific membrane glycoproteins in total platelet lysates. This monoclonal antibody (MAb) capture assay takes into account the fact that antibodies on circulating platelets may be translocated to internal pools as well as being on the surface. A total of twenty ITP patients were examined by PAICA, and the results compared with those obtained by measuring (i) serum antibodies bound to paraformaldehyde-fixed control platelets by ELISA, (ii) IgG bound to the surface of the patient's own platelets by flow cytometry (PSIgG), (iii) total platelet-associated IgG (PAIgG) by ELISA and (iv) serum antibodies reacting with control platelets by MAIPA ("Monoclonal Antibody-specific Immobilization of Platelet Antigens"). Of twelve patients with elevated PAIgG, nine had increased PSIgG yet eleven reacted positively in PAICA. Of these, eight possessed antibodies directed against GP IIb-IIIa, two against GP Ib-IX and one patient possessed antibodies directed against GP IIb-IIIa and GP Ia-IIa respectively. Only seven of the patients possessed serum antibodies detectable by MAIPA. PAICA was also able to detect platelet-associated c7E3 (the chimeric form of Fab fragments of the MAb 7E3) following its infusion during antithrombotic therapy, when it proved more sensitive over a seven-day period than a MAIPA assay adapted for assessing surface-bound antibody. We propose that PAICA provides added sensitivity to the detection of platelet-associated antibodies in immune thrombocytopenias or following therapy with humanized MAbs.
Asunto(s)
Antígenos de Plaqueta Humana/inmunología , Autoanticuerpos/análisis , Inmunoensayo/métodos , Inmunoglobulina G/análisis , Púrpura Trombocitopénica Idiopática/inmunología , Adulto , Anciano , Autoanticuerpos/inmunología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Inhibidores de Agregación Plaquetaria/análisis , Inhibidores de Agregación Plaquetaria/inmunología , Sensibilidad y EspecificidadRESUMEN
The treatment of bleeds in Glanzmann's thrombasthenia is a challenging issue, especially when repeated platelet transfusions have induced anti-glycoprotein (GP) IIb-IIIa or anti-HLA allo-immunisation. In an attempt to find an alternative treatment regimen, we used recombinant factor VIIa (rFVIIa, NovoSeven, Novo Nordisk, Denmark) as first-line therapy in 3 patients with Glanzmann's thrombasthenia and anti-GPIIb-IIIa iso-antibodies who were scheduled for invasive procedures. The administration of an initial bolus dose of rFVIIa (70-110 microg/kg) was immediately followed by continuous infusion at the rate of 9-30 microg/kg/h for 3-15 days. The treatment resulted in an excellent clinical efficacy and tolerance in 2 cases. In the third patient, whereas efficacy was excellent at the surgical site, pharyngonasal bleeds of traumatic origin persisted for 10 days, and a severe thromboembolic complication occurred 5 days after discontinuation of rFVIIa. Complementary studies are needed for patients with congenital platelet disorders in order to evaluate the safety and the potential therapeutic place of rFVIIa treatment.
Asunto(s)
Factor VIIa/uso terapéutico , Trombastenia/tratamiento farmacológico , Adenocarcinoma/complicaciones , Adenocarcinoma/cirugía , Adulto , Anciano , Colecistectomía , Colectomía , Neoplasias del Colon/complicaciones , Neoplasias del Colon/cirugía , Femenino , Genes Recesivos , Humanos , Laparotomía , Masculino , Persona de Mediana Edad , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/inmunología , Proteínas Recombinantes/uso terapéutico , Trombastenia/complicacionesRESUMEN
The only known function of the 41 amino acid cleaved peptide (TR1-41) of the seven transmembrane domain thrombin receptor (PARI) is to activate platelets (as determined by aggregation, surface P-selectin, and fibrinogen binding to activated GPIIb-IIIa). We now demonstrate that TR1-41 results in a concentration-dependent decrease in the platelet surface expression of each component of the GPIb-IX-V complex, as determined by flow cytometry with a panel of monoclonal antibodies (including 6D1, directed against the von Willebrand factor binding site on GPIbalpha, and TM60, directed against the thrombin binding site on GPIbalpha). TR1-41 also decreased ristocetin-induced platelet agglutination. Immunoblotting after incubation of platelets with TR1-41 revealed neither a loss of platelet GPIb nor increase in supernatant GPIb fragments. As demonstrated by immunoelectron microscopy, TR1-41 resulted in a redistribution of GPIb, GPIX, and GPV from the platelet surface to the surface-connected canalicular system (SCCS). In summary, the cleaved peptide (TR1-41) of PAR1 results in a redistribution of the platelet surface GPIb-IX-V complex to the SCCS, thereby negatively regulating the GPIbalpha binding sites for von Willebrand factor and thrombin.
Asunto(s)
Plaquetas/metabolismo , Complejo GPIb-IX de Glicoproteína Plaquetaria/metabolismo , Glicoproteínas de Membrana Plaquetaria , Receptores de Trombina/metabolismo , Trombina/metabolismo , Animales , Humanos , Ratones , Transducción de Señal , Factor de von Willebrand/metabolismoRESUMEN
We have investigated the type of platelet defect that can be detected with the Hemostatus test performed with the Hepcon/HMS instrument (Medtronic) designed to investigate platelet function during and after surgery. This assay is based on the comparison of the activated clotting time of whole blood measured in cartridges containing kaolin or kaolin and platelet-activating factor in different concentrations. Addition of platelet-activating factor shortened the blood activated clotting time when the platelet counts were normal. However, when platelet counts were below 70000/microL, the activated clotting time was prolonged in all channels including those without platelet-activating factor showing the influence of platelets in the formation of the clot under the conditions tested. Inhibition of platelet aggregation with c7E3 (abciximab, ReoPro) also induced a much-prolonged activated clotting time, and a similar finding was seen with blood from a patient with Glanzmann's thrombasthenia confirming the need for platelet aggregation and/or the glycoprotein (GP) IIb-IIIa complex. In contrast, the interaction of GP Ib with von Willebrand Factor was not of major importance, since inhibition of this interaction with the anti-GP Ib murine monoclonal antibody, ALMA-12, did not modify the activated clotting time. Furthermore, the activated clotting time measured for patients with an acquired defect in von Willebrand Factor activity were unchanged. Finally, inhibition of thromboxane A2 formation by aspirin did not influence the results of this test. Globally, the Hemostatus test was able to detect major abnormalities of GP IIb-IIIa function in the presence or absence of platelet-activating factor.
Asunto(s)
Anticuerpos Monoclonales/farmacología , Aspirina/farmacología , Pruebas de Coagulación Sanguínea/métodos , Fragmentos Fab de Inmunoglobulinas/farmacología , Agregación Plaquetaria/efectos de los fármacos , Abciximab , Adulto , Anticoagulantes/farmacología , Humanos , Inhibidores de Agregación Plaquetaria/farmacología , Recuento de Plaquetas , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/antagonistas & inhibidores , Trombastenia/patología , Factores de Tiempo , Factor de von Willebrand/farmacologíaRESUMEN
Inherited platelet defects bleeding syndromes underlie of varying severity. The Bernard-Soulier syndrome and Glanzmann thrombasthenia are disorders of membrane glycoproteins. In the former, a deficiency of the GPIb-IX-V complex leads to defective platelet adhesion, while in thrombasthenia, platelet aggregation does not occur in the absence of the integrin alphaIIbbeta3. Defects of primary receptors for stimuli are increasingly being described, and include a defect of a newly cloned Gi-protein-linked, seven transmembrane domain, ADP receptor. These lead to agonist-specific deficiencies in the platelet function response, as do abnormalities in the many intracellular signaling pathways of platelets. Defects affecting secretion from dense bodies and alpha-granules, of ATP production and generation of procoagulant activity, are also encountered. Some disorders are exclusive to megakaryocytes and platelets, while in others, such as the Chediak-Higashi, Hermansky-Pudlak and Wiskott-Aldrich syndromes; the molecular lesion extends to other cell types. Disorders affecting platelet morphology, the so-called "giant platelet" syndromes should also be considered. In familial thrombocytopenias, platelets are produced in insufficient quantities to assure hemostasis. Platelet disorders are examples of rare diseases; nevertheless they have provided essential information in the elucidation of the molecular basis of platelet function.
Asunto(s)
Trastornos de la Coagulación Sanguínea Heredados/etiología , Trastornos de las Plaquetas Sanguíneas/etiología , Animales , Trastornos de la Coagulación Sanguínea Heredados/metabolismo , Trastornos de la Coagulación Sanguínea Heredados/patología , Trastornos de las Plaquetas Sanguíneas/metabolismo , Trastornos de las Plaquetas Sanguíneas/patología , Salud de la Familia , Humanos , Activación Plaquetaria/genética , Glicoproteínas de Membrana Plaquetaria/genética , Glicoproteínas de Membrana Plaquetaria/metabolismo , Glicoproteínas de Membrana Plaquetaria/fisiología , Transducción de Señal/genéticaRESUMEN
We report the detection of activated GP IIb-IIIa complexes on platelets of patients undergoing thrombolytic therapy after acute myocardial infarction. Protocols were established for the monoclonal antibodies (mAbs): VH10, anti-P-selectin, a marker of platelet secretion; 9F9 and F26, two anti-RIBS (receptor-induced binding sites) mAbs specific for fibrinogen (Fg) bound to the GP IIb-IIIa receptor. Of ten patients studied: two were treated with streptokinase, four with APSAC (anisoylated plasminogen-streptokinase activator complex), and three with rt-PA. Platelets were tested on at least five occasions in the week following therapy. The percentage of platelets positive with 9F9 was often high, and reached a maximum within three days. By this time, plasma Fg levels, which fell during fibrinolysis, had begun to return to normal. Levels of activated platelets had fallen to baseline after 7 days. PAC-1, a mAb which binds directly to the activated GP IIb-IIIa complex, confirmed the results with 9F9, but F26 was a less sensitive probe. Binding of the anti-P-selectin mAb (VH10) was low, showing that little secretion had occurred. A concentration-dependent inhibition of 9F9 binding by RGDW peptide, a competitive inhibitor for Fg on GP IIb-IIIa, confirmed that Fg (or epitope-containing degradation products) were being located by the antibody. The activation of GP IIb-IIIa occurred despite the patients receiving aspirin and heparin. Thus platelets of some fibrinolytic patients have an increased tendency for surface activation within the first 72 h after treatment, a finding which would be compatible with an increased thrombotic tendency.
Asunto(s)
Plaquetas/metabolismo , Citometría de Flujo , Infarto del Miocardio/sangre , Infarto del Miocardio/tratamiento farmacológico , Glicoproteínas de Membrana Plaquetaria/metabolismo , Terapia Trombolítica , Adulto , Anciano , Secuencia de Aminoácidos , Anistreplasa/uso terapéutico , Anticuerpos Monoclonales , Femenino , Humanos , Cinética , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Activación Plaquetaria , Recuento de Plaquetas , Proteínas Recombinantes/uso terapéutico , Estreptoquinasa/uso terapéutico , Activador de Tejido Plasminógeno/uso terapéuticoRESUMEN
Idiopathic thrombotycopenic purpura (ITP) is an autoimmune disorder in which circulating autoantibodies react with target antigens on the platelet membrane. In order to identify the autoimmune response in ITP, two MAIPA (Monoclonal Antibody (MAb) Immobilization of Platelet Antigen) assays (MAIPA I and MAIPA II) were performed on sera from thrombocytopenic patients. In the classic MAIPA assay (MAIPA I), control platelets were incubated simultaneously with human serum and a mouse MAb to a platelet glycoprotein. In MAIPA II, the control platelets were incubated first with the human serum and then, after washing, with the selected mouse MAb. A positive MAIPA I test but a negative MAIPA II has been shown to result from the presence of serum antibodies recognizing mouse MAb to platelet glycoproteins used in the assay. We compared the frequency of such 'anti-mouse' antibodies in patients with thrombocytopenia associated or not with other autoimmune states and in healthy donors with a normal platelet count. Statistically significant differences were found in the incidence of anti-mouse antibodies between patients and healthy donors. Furthermore, the identity of the targeted mouse MAbs varied in sera from the patients. The detected anti-mouse antibodies may include anti-idiotypic antibodies produced against cross-reactive idiotypes shared by human and mouse anti-platelet antibodies.
Asunto(s)
Anticuerpos Antiidiotipos/inmunología , Anticuerpos Heterófilos/inmunología , Anticuerpos Monoclonales/inmunología , Antígenos de Plaqueta Humana/inmunología , Autoanticuerpos/inmunología , Enfermedades Autoinmunes/inmunología , Ratones/inmunología , Glicoproteínas de Membrana Plaquetaria/inmunología , Trombocitopenia/inmunología , Adolescente , Adulto , Anciano , Anemia Hemolítica Autoinmune/complicaciones , Anemia Hemolítica Autoinmune/inmunología , Animales , Anticuerpos Heterófilos/sangre , Especificidad de Anticuerpos , Síndrome Antifosfolípido/complicaciones , Síndrome Antifosfolípido/inmunología , Artritis Reumatoide/complicaciones , Artritis Reumatoide/inmunología , Autoanticuerpos/sangre , Enfermedades Autoinmunes/sangre , Plaquetas/inmunología , Reacciones Cruzadas , Femenino , Humanos , Cirrosis Hepática Biliar/complicaciones , Cirrosis Hepática Biliar/inmunología , Lupus Eritematoso Sistémico/complicaciones , Lupus Eritematoso Sistémico/inmunología , Masculino , Persona de Mediana Edad , Púrpura Trombocitopénica Idiopática/sangre , Púrpura Trombocitopénica Idiopática/inmunología , Trombocitopenia/sangre , Tiroiditis Autoinmune/complicaciones , Tiroiditis Autoinmune/inmunologíaRESUMEN
Therapy involving the use of anti-GPIIb-IIIa inhibitors has progressively evolved in recent years for patients undergoing percutaneous coronary intervention or with acute coronary syndromes. Patients receiving anti-GP IIb-IIIa therapy have a lower risk of death or myocardial infarction than those receiving the classic anti-agregant, aspirin, alone. Two classes of products have been used in clinic, the chimeric monoclonal antibody Fab fragment, c7E3 or abciximab (ReoPro), which has been the pioneer, and synthetic peptides or peptidomimetics such as eptifibatide (Integrilin) or tirofiban (Agrastat). Abciximab is a long-acting, high-affinity receptor blocker, whereas eptifibatide and tirofiban have much shorter biological half-lives. Another property that differentiates these compounds is that the peptides bind exclusively to GP IIb-IIIa whereas c7E3 also binds to alpha v beta 3, the vitronectin receptor. The potent inhibitory effect of these compounds increases the risk of bleeding. By carefully controlling the levels of heparin and by removing the sheath as early as possible, the hemorrhagic problems may be limited. Another potential complication is the rapid development of thrombocytopenia. The cause has yet to be found and for c7E3 no correlation with the development of HACA (human anti-chimeric antibodies) has been observed. Because of the chronic nature of coronary artery disease, evaluation of the readministration of c7E3 to the same patient two or even more times is under investigation. The first results do not show major problems. The best biological way to investigate the efficiency of anti-GPIIb-IIIa has to be determined. Interestingly, a new point-of-care test has been proposed, while monoclonal antibodies are available that differentiate between nonoccupied and occupied GPIIb-IIIa complexes.
Asunto(s)
Angioplastia Coronaria con Balón , Enfermedad Coronaria/tratamiento farmacológico , Inhibidores de Agregación Plaquetaria/uso terapéutico , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/antagonistas & inhibidores , Tirosina/análogos & derivados , Abciximab , Anticuerpos Monoclonales/uso terapéutico , Aspirina/uso terapéutico , Eptifibatida , Humanos , Fragmentos Fab de Inmunoglobulinas/uso terapéutico , Infarto del Miocardio/prevención & control , Péptidos/uso terapéutico , Tirofibán , Tirosina/uso terapéuticoRESUMEN
Structural changes in blood vessels associated with atherosclerosis are at the onset of arterial thrombosis. Thrombi form at the sites of plaque rupture. Plateletrich masses accumulate in the vessel lumen perturb blood flow, thereby aggravating ischemic syndromes. Other local modifications include the recruitment of cells with inflammatory and immunologic potential, showing how complicated this process is. The demonstration that aspirin lowered the number of thrombotic events was an important step in proving the value of anti-platelet therapy. Since then, newer strategies involving drugs acting on the fibrinogen receptor (the GPIIb-IIIa complex) or on ADP receptors have evolved largely as a result of the increased knowledge of the biological pathways of platelet aggregation. These drugs have given superior results in many international trials and their usefulness in interventional cardiology has been proven. Such encouraging progress also incites efforts to find new and improved targets for anti-platelet therapy as well as testing new associations of existing anti-platelet drugs which may also be used with anticoagulant therapies, and in the future, be combined with drugs directly preventing restenosis.